Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii
Open Access
- 25 April 2019
- journal article
- research article
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 20 (1) , 19
Abstract
Tigecycline, with broad in vitro antibacterial activity, has been widely used off-label for nosocomial pneumonia caused by multi-drug resistant Acinetobacter baumannii (MDRAB). However, many concerns have been raised about the efficacy of tigecycline treatment as the inconsistent results from previous clinical studies. This retrospective study evaluated the outcome of adult patients with monomicrobial MDRAB nosocomial pneumonia treated with tigecycline between 2015 and 2017. Results. A total of 77 patients was eligible for this study, and the overall clinical success and 30-day survival rates were 70.03 and 70.13%, respectively, however, the microbiological eradication rate was relatively low (48%). Multivariate analysis indicated that shorter duration of tigecycline use associated with increased clinical failure, whereas higher CURB65 scores, mechanical ventilation and tigecycline resistant to MDRAB have significant association with 30-day mortality. Our results suggest that tigecycline is one of the potential choices for the treatment of hospital-acquired pneumonia caused by MDRAB, especially with a MIC≤2 mg/L. In addition, a longer duration of tigecycline treatment may be required to insure better clinical outcomes.Keywords
Funding Information
- Natural Science Foundation of Hunan Province (2018JJ3771)
This publication has 27 references indexed in Scilit:
- Bloodstream infections caused by Acinetobacter species with reduced susceptibility to tigecycline: clinical features and risk factorsInternational Journal of Infectious Diseases, 2017
- Treatment of severe hospital-acquired and ventilator-associated pneumonia: a systematic review of inclusion and judgment criteria used in randomized controlled trialsCritical Care, 2017
- Using Procalcitonin to Guide Antibiotic TherapyOpen Forum Infectious Diseases, 2016
- Clinical Features and Risk Factors for Development of Breakthrough Gram-Negative Bacteremia during Carbapenem TherapyAntimicrobial Agents and Chemotherapy, 2016
- Efficacy and Safety of Tigecycline for Patients with Hospital-Acquired PneumoniaChemotherapy, 2016
- Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumanniiin a critical setting: a matched cohort analysisBMC Infectious Diseases, 2014
- Pharmacological and Patient-Specific Response Determinants in Patients with Hospital-Acquired Pneumonia Treated with TigecyclineAntimicrobial Agents and Chemotherapy, 2012
- Is Tigecycline a Good Choice in the Treatment of Multidrug-ResistantAcinetobacter baumanniiPneumonia?Journal of Chemotherapy, 2011
- Late Onset Ventilator-Associated Pneumonia Due to Multidrug-Resistant Acinetobacter spp.: Experience with TigecyclineJournal of Chemotherapy, 2009
- Validation and Application of the Pneumonia Prognosis Index to Nursing Home Residents with PneumoniaJournal of the American Geriatrics Society, 1998